Mechanism of Ph positive leukemia cell maintenance by Hippo pathway
Project/Area Number |
26430171
|
Research Category |
Grant-in-Aid for Scientific Research (C)
|
Allocation Type | Multi-year Fund |
Section | 一般 |
Research Field |
Tumor therapeutics
|
Research Institution | Tokyo Medical University |
Principal Investigator |
Okabe Seiichi 東京医科大学, 医学部, 講師 (40366109)
|
Co-Investigator(Kenkyū-buntansha) |
伊藤 良和 東京医科大学, 医学部, 教授 (10287120)
|
Project Period (FY) |
2014-04-01 – 2017-03-31
|
Project Status |
Completed (Fiscal Year 2016)
|
Budget Amount *help |
¥5,200,000 (Direct Cost: ¥4,000,000、Indirect Cost: ¥1,200,000)
Fiscal Year 2016: ¥780,000 (Direct Cost: ¥600,000、Indirect Cost: ¥180,000)
Fiscal Year 2015: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
Fiscal Year 2014: ¥2,470,000 (Direct Cost: ¥1,900,000、Indirect Cost: ¥570,000)
|
Keywords | AMPK / Ph陽性白血病 |
Outline of Final Research Achievements |
We made BCR-ABL positive iPS cells and analyze the phenotype, cell proliferation and efficacy of ABL inhibitors in iPS cells. Because the association between AMPK and Hippo pathway has been reported, we investigated the effect of AMPK on Ph-positive leukemia. Pioglitazone induced cell growth inhibition in a concentration-dependent manner in Ph-positive leukemia cells and enhanced AMPK phosphorylation. Co-treatment with pioglitazone and ABL inhibitor decreased the expression of BCR-ABL in CML patient. Pioglitazone may possess promising clinical relevance as a candidate therapeutic agent for Ph-positive leukemia in the future.
|
Report
(4 results)
Research Products
(1 results)